Latest From Sten Stovall
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.